Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial

Erstveröffentlichung
2018Authors
Cortes, Jorge
Perl, Alexander E.
Döhner, Hartmut
Kantarjian, Hagop
Martinelli, Giovanni
Wissenschaftlicher Artikel
Published in
Lancet Oncology ; 19 (2018), 7. - S. 889-903. - ISSN 1470-2045. - eISSN 1474-5488